LWANC
PLRX icon

Laurel Wealth Advisors (North Carolina)’s Pliant Therapeutics PLRX Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-160
Closed -$1K – 591
2022
Q2 		$1K Hold
160
– – ﹤0.01% 602
2022
Q1 		$1K Hold
160
– – ﹤0.01% 639
2021
Q4 		$2K Hold
160
– – ﹤0.01% 596
2021
Q3 		$3K Hold
160
– – ﹤0.01% 558
2021
Q2 		$5K Buy
+160
New +$4.98K ﹤0.01% 551

Other funds holding PLRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s PLRX Position: Q3 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Pliant Therapeutics (PLRX) in Q3 2022, closing a stake of 160 shares — an estimated $1K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in PLRX in Q2 2021 and held it in 5 quarters. The position peaked at $5K in Q2 2021. 110 funds tracked by Wall St. Rank hold PLRX as of Q3 2022.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Pliant Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 160 Pliant Therapeutics shares in Q3 2022, an estimated $1K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Pliant Therapeutics in Q2 2021 and held it in 5 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Pliant Therapeutics position peaked at $5K in Q2 2021.
  • 110 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2022, filed 15 Nov 2022.